10-Q Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 Q3 2016

Filing Information

Form Type	10-Q
Accession Number	`0001144204-16-132840`
Period End Date	20160930
Filing Date	20161109
Fiscal Year	2016
Fiscal Period	Q3
XBRL Instance	bpth-20160930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 62 Income Statement 44 Cash Flow Statement 40

Balance Sheet 62 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$9.86M	USD	Point-in-time
Cash	`Cash`	$13.86M	USD	Point-in-time
Cash	`Cash`	$8.85M	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$11.30M	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$196.00K	USD	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product for testing	`PrepaidExpenseCurrent`	$560.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$912.00K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$179.00K	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$9.59M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$12.41M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	95.65M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	89.76M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$123.00K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	89.76M	shares	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	95.65M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$148.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$82.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$51.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$66.00K	USD	Point-in-time
Property, Plant and Equipment, Net	`PropertyPlantAndEquipmentNet`	$72.00K	USD	Point-in-time
Technology licenses	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Technology licenses	`FiniteLivedLicenseAgreementsGross`	$2.50M	USD	Point-in-time
Less accumulated amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$1.41M	USD	Point-in-time
Less accumulated amortization	`FiniteLivedIntangibleAssetsAccumulatedAmortization`	$1.53M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$1.09M	USD	Point-in-time
Intangible Assets, Net (Excluding Goodwill), Total	`IntangibleAssetsNetExcludingGoodwill`	$969.00K	USD	Point-in-time
Total Assets	`Assets`	$10.76M	USD	Point-in-time
Total Assets	`Assets`	$13.44M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$118.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$54.00K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$748.00K	USD	Point-in-time
Accrued expense	`AccruedLiabilitiesCurrent`	$883.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$937.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$866.00K	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	$3.20M	USD	Point-in-time
Warrant liability	`DerivativeLiabilitiesNoncurrent`	-	USD	Point-in-time
Total Liabilities	`Liabilities`	$4.07M	USD	Point-in-time
Total Liabilities	`Liabilities`	$937.00K	USD	Point-in-time
Preferred stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value, 200,000,000 shares authorized 95,645,224 and 89,762,872 shares issued and outstanding as of 9/30/16 and 12/31/15, respectively	`CommonStockValue`	$96.00K	USD	Point-in-time
Common stock, $.001 par value, 200,000,000 shares authorized 95,645,224 and 89,762,872 shares issued and outstanding as of 9/30/16 and 12/31/15, respectively	`CommonStockValue`	$90.00K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$40.04M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$35.11M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-25.38M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-30.76M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$9.38M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$9.82M	USD	Point-in-time
Total Liabilities & Shareholders Equity	`LiabilitiesAndStockholdersEquity`	$10.76M	USD	Point-in-time
Total Liabilities & Shareholders Equity	`LiabilitiesAndStockholdersEquity`	$13.44M	USD	Point-in-time

Income Statement 44 line items

Line Item	Tag	Value	Unit	Period
Revenue	`Revenues`	-	USD	3 Qtrs
Revenue	`Revenues`	-	USD	3 Qtrs
Revenue	`Revenues`	-	USD	1 Quarter
Revenue	`Revenues`	-	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$992.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.31M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.15M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$4.52M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$2.29M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$520.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.87M	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$681.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$6.81M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$4.02M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$2.99M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.51M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-1.51M	USD	1 Quarter
Net operating loss	`OperatingIncomeLoss`	$-4.02M	USD	3 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-6.81M	USD	3 Qtrs
Net operating loss	`OperatingIncomeLoss`	$-2.99M	USD	1 Quarter
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	-	USD	3 Qtrs
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	$-1.42M	USD	3 Qtrs
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	$-1.42M	USD	1 Quarter
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$14.00K	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$8.00K	USD	3 Qtrs
Interest income	`InvestmentIncomeInterest`	$4.00K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$4.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$1.42M	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$14.00K	USD	3 Qtrs
Total other income	`NonoperatingIncomeExpense`	$4.00K	USD	1 Quarter
Total other income	`NonoperatingIncomeExpense`	$1.43M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.57M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.38M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.01M	USD	3 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.06	USD	3 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	3 Qtrs
Net loss per share, basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	91,724.00	shares	3 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	95,645.00	shares	1 Quarter
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89,763.00	shares	3 Qtrs
Basic and diluted weighted average number of common shares outstanding	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89,763.00	shares	1 Quarter

Cash Flow Statement 40 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.57M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-5.38M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.51M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.01M	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$121.00K	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$121.00K	USD	3 Qtrs
Depreciation	`Depreciation`	$31.00K	USD	3 Qtrs
Depreciation	`Depreciation`	$31.00K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$550.00K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$283.00K	USD	3 Qtrs
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	-	USD	3 Qtrs
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	$-1.42M	USD	3 Qtrs
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	$-1.42M	USD	1 Quarter
Change in fair value of warrant liability	`FairValueAdjustmentOfWarrants`	-	USD	1 Quarter
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$250.00K	USD	3 Qtrs
Prepaid drug product for testing	`IncreaseDecreaseInPrepaidExpense`	$-364.00K	USD	3 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$100.00K	USD	3 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$733.00K	USD	3 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-81.00K	USD	3 Qtrs
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-71.00K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-6.54M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-4.00M	USD	3 Qtrs
Purchase furniture, fixtures & equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	-	USD	3 Qtrs
Purchase furniture, fixtures & equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$25.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	-	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-25.00K	USD	3 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$9.01M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$9.01M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	-	USD	3 Qtrs
Net increase (decrease) in cash	`CashPeriodIncreaseDecrease`	$2.44M	USD	3 Qtrs
Net increase (decrease) in cash	`CashPeriodIncreaseDecrease`	$-4.00M	USD	3 Qtrs
Cash, beginning of period	`Cash`	$9.86M	USD	Point-in-time
Cash, beginning of period	`Cash`	$13.86M	USD	Point-in-time
Cash, beginning of period	`Cash`	$8.85M	USD	Point-in-time
Cash, beginning of period	`Cash`	$11.30M	USD	Point-in-time
Cash, end of period	`Cash`	$9.86M	USD	Point-in-time
Cash, end of period	`Cash`	$13.86M	USD	Point-in-time
Cash, end of period	`Cash`	$8.85M	USD	Point-in-time
Cash, end of period	`Cash`	$11.30M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.